Literature DB >> 26888952

Time to redefine success? TICI 3 versus TICI 2b recanalization in middle cerebral artery occlusion treated with thrombectomy.

Justus F Kleine1, Silke Wunderlich2, Claus Zimmer1, Johannes Kaesmacher1.   

Abstract

BACKGROUND: The Thrombolysis in Cerebral Infarction (TICI) scale is the most widely applied scoring system to grade technical results of recanalizing therapies in acute ischemic stroke (AIS). TICI 2b and TICI 3 are conventionally subsumed as 'successful recanalization'. Previous studies reported conflicting results for the clinical relevance of achieving complete (TICI 3) versus 'almost' complete reperfusion (TICI 2b).
OBJECTIVE: To examine if neurologic outcome differs significantly between TICI 2b and TICI 3 in patients with AIS with middle cerebral artery (MCA) occlusion treated 'successfully' with mechanical thrombectomy (MTE).
METHODS: Retrospective analysis of prospectively collected data from 352 consecutive patients with isolated MCA occlusion subjected to MTE between January 2007 and July 2015.
RESULTS: 262 of the 277 successfully treated patients had adequate follow-up and were included. Patients (n=119) in the TICI 3 group had a lower National Institutes of Health Stroke Scale score at discharge (NIHSS-DIS; median 5 vs 7, p=0.005), and showed higher rates of strong neurologic improvement (ΔNIHSS≥8 or NIHSS-DIS≤1, 68.4% vs 37.1%, p=0.002) and favorable NIHSS outcome (NIHSS-DIS≤5, 49.2% vs 31.9%, p=0.005). Hospital stays were shorter in the TICI 3 group (median 10 vs 12 days, p=0.014). After adjusting for relevant baseline and treatment parameters, TICI 3 was independently associated with strong neurologic improvement (OR=4.3, 95% CI 2.2 to 8.3, p<0.001) and favorable NIHSS outcome (OR=3.0, 95% CI 1.5 to 6.3, p=0.003).
CONCLUSIONS: Neurologic outcome is substantially better in TICI 3 than TICI 2b patients, and hospital stays are shorter. Endovascular strategies that consequently strive to achieve TICI 3 may be warranted and cost-effective, and should be examined by future research. TICI 3 rates should be included as a safety measure in studies evaluating MTE devices and techniques. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Stroke; Thrombectomy

Mesh:

Year:  2016        PMID: 26888952     DOI: 10.1136/neurintsurg-2015-012218

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  43 in total

1.  Aspiration thrombectomy in clinical routine interventional stroke treatment : Is this the end of the stent retriever era?

Authors:  S Prothmann; B Friedrich; T Boeckh-Behrens; C Zimmer; J Kaesmacher; K Lucia; C Maegerlein
Journal:  Clin Neuroradiol       Date:  2017-01-12       Impact factor: 3.649

2.  Clinical outcome prediction after thrombectomy of proximal middle cerebral artery occlusions by the appearance of lenticulostriate arteries on magnetic resonance angiography: A retrospective analysis.

Authors:  Johannes Kaesmacher; Kornelia Kreiser; Nathan W Manning; Alexandra S Gersing; Silke Wunderlich; Claus Zimmer; Justus F Kleine; Benedikt Wiestler; Tobias Boeckh-Behrens
Journal:  J Cereb Blood Flow Metab       Date:  2017-07-24       Impact factor: 6.200

3.  Striving for the Best: How Far Should We Go? Regarding "Impact of Modified TICI 3 versus Modified TICI 2b Reperfusion Score to Predict Good Outcome following Endovascular Therapy".

Authors:  J Kaesmacher
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-31       Impact factor: 3.825

4.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke.

Authors:  D Sacks; B Baxter; B C V Campbell; J S Carpenter; C Cognard; D Dippel; M Eesa; U Fischer; K Hausegger; J A Hirsch; M S Hussain; O Jansen; M V Jayaraman; A A Khalessi; B W Kluck; S Lavine; P M Meyers; S Ramee; D A Rüfenacht; C M Schirmer; D Vorwerk
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-17       Impact factor: 3.825

5.  3MAX catheter for thromboaspiration of downstream and new territory emboli after mechanical thrombectomy of large vessel occlusions: initial experience.

Authors:  Fabio Settecase
Journal:  Interv Neuroradiol       Date:  2018-11-21       Impact factor: 1.610

6.  Improving mTICI2b reperfusion to mTICI2c/3 reperfusions: A retrospective observational study assessing technical feasibility, safety and clinical efficacy.

Authors:  Johannes Kaesmacher; Christian Maegerlein; Felix Zibold; Silke Wunderlich; Claus Zimmer; Benjamin Friedrich
Journal:  Eur Radiol       Date:  2017-07-27       Impact factor: 5.315

7.  Biomechanics and hemodynamics of stent-retrievers.

Authors:  Anna Luisa Kühn; Zeynep Vardar; Afif Kraitem; Robert M King; Vania Anagnostakou; Ajit S Puri; Matthew J Gounis
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

8.  Ischemic lesion water homeostasis after thrombectomy for large vessel occlusion stroke within the anterior circulation: The impact of age.

Authors:  Lukas Meyer; Michael Schönfeld; Matthias Bechstein; Uta Hanning; Bastian Cheng; Götz Thomalla; Gerhard Schön; Andre Kemmling; Jens Fiehler; Gabriel Broocks
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-04       Impact factor: 6.200

9.  Prediction of mTICI 3 recanalization and clinical outcomes in endovascular thrombectomy for acute ischemic stroke: a retrospective study in the Taiwan registry.

Authors:  Ching-Chung Ko; Hon-Man Liu; Tai-Yuan Chen; Te-Chang Wu; Li-Kai Tsai; Sung-Chun Tang; Yu-Kun Tsui; Jiann-Shing Jeng
Journal:  Neurol Sci       Date:  2020-10-10       Impact factor: 3.307

10.  Impact of Modified TICI 3 versus Modified TICI 2b Reperfusion Score to Predict Good Outcome following Endovascular Therapy.

Authors:  C Dargazanli; A Consoli; M Barral; J Labreuche; H Redjem; G Ciccio; S Smajda; J P Desilles; G Taylor; C Preda; O Coskun; G Rodesch; M Piotin; R Blanc; B Lapergue
Journal:  AJNR Am J Neuroradiol       Date:  2016-11-03       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.